Table 2. A comparison between clinical characteristics of germline BRCA1/2 variant carriers and non-carriers.
| Characteristics | Non-carriers No. (n = 385) | Germline BRCA1/2 P/LP variants carriers No. (n = 40) | Germline BRCA1/2 VUS carriers No. (n = 62) | |||||
|---|---|---|---|---|---|---|---|---|
| BRCA1/2 (n = 40) | P a | BRCA1 (n = 18) | P a | BRCA2 (n = 22) | P a | |||
| Age at diagnosis (y, mean±SD) | 50.7±10.3 | 46.6±8.5 | 0.01 | 46.9±9.4 | 0.13 | 46.2±8.0 | 0.05 | 48.5±9.2 |
| Family history of breast cancer | ||||||||
| Yes | 12 | 3 | 0.16 | 0 | 1.00 | 3 | 0.04 | 1 |
| No | 373 | 37 | 18 | 19 | 61 | |||
| Menopause at diagnosis | ||||||||
| Postmenopause | 176 | 13 | 0.10 | 6 | 0.29 | 7 | 0.19 | 23 |
| Premenopause | 206 | 27 | 12 | 15 | 39 | |||
| Molecular subtype | ||||||||
| Luminal A | 49 | 1 | < 0.001 | 0 | < 0.001 | 1 | 0.41 | 10 |
| Luminal B | 218 | 21 | 4 | 17 | 35 | |||
| HER2+ | 57 | 1 | 0 | 1 | 8 | |||
| TN | 48 | 14 | 11 | 3 | 6 | |||
| ER-PR+ | 13 | 3 | 3 | 0 | 3 | |||
| ER | ||||||||
| Positive (>1%) | 274 | 22 | 0.03 | 4 | < 0.001 | 18 | 0.28 | 47 |
| Negative | 111 | 18 | 14 | 4 | 15 | |||
| PR | ||||||||
| Positive (>1%) | 266 | 22 | 0.07 | 6 | 0.002 | 16 | 0.72 | 43 |
| Negative | 119 | 18 | 12 | 6 | 19 | |||
| Ki67 | ||||||||
| <14% | 68 | 1 | 0.01 | 0 | 0.05 | 1 | 0.15 | 12 |
| ≥14% | 315 | 39 | 18 | 21 | 50 | |||
| HER2 | ||||||||
| Positive | 130 | 2 | < 0.001 | 0 | 0.003 | 2 | 0.02 | 18 |
| Negative | 255 | 38 | 18 | 20 | 44 | |||
| Histology | ||||||||
| DCIS | 3 | 0 | 0.05 | 0 | 0.34 | 0 | 0.28 | 2 |
| Invasive ductal carcinoma | 341 | 40 | 18 | 22 | 53 | |||
| Other Invasive carcinomas | 41 | 0 | 0 | 0 | 7 | |||
| Histological grade | ||||||||
| I/II | 126 | 8 | 0.06 | 1 | 0.01 | 7 | 0.73 | 25 |
| III | 230 | 31 | 16 | 15 | 33 | |||
| T | ||||||||
| Tis/T1 | 128 | 11 | 0.76 | 4 | 0.70 | 7 | 1.00 | 20 |
| T2 | 227 | 26 | 13 | 13 | 36 | |||
| T3 | 17 | 1 | 1 | 0 | 3 | |||
| T4 | 11 | 0 | 0 | 0 | 3 | |||
| No. of lymph node involvement | ||||||||
| 0 | 166 | 22 | 0.28 | 11 | 0.32 | 11 | 0.71 | 33 |
| 1~3 | 133 | 10 | 4 | 6 | 22 | |||
| ≥4 | 85 | 7 | 3 | 4 | 7 | |||
| M | ||||||||
| M0 | 381 | 38 | 0.07 | 16 | 0.02 | 22 | 1.00 | 62 |
| M1 | 3 | 2 | 2 | 0 | 0 | |||
| Clinical stage | ||||||||
| 0/I | 60 | 7 | 0.13 | 2 | 0.04 | 5 | 0.62 | 12 |
| II | 227 | 22 | 11 | 11 | 40 | |||
| III | 93 | 7 | 3 | 4 | 10 | |||
| VI | 3 | 2 | 2 | 0 | 0 | |||
| Standard therapy | ||||||||
| Yes | 15 | 2 | 0.67 | 0 | 1.00 | 2 | 0.23 | 4 |
| No | 370 | 38 | 18 | 20 | 58 | |||
a P-value calculated comparing with non-carriers by two-tailed t-tests, Pearson Chi-Square tests, or Fisher's Exact tests as appropriate. Unknown data were not included in the analysis.